Freshmedx Venture to Bring Life Saving Technology to Millions at risk of Lung Cancer in Japan

June 10, 2011— Freshmedx today announced a joint venture that will bring life saving technology to over 62 million people in Japan who are at high risk of developing lung cancer. The Salt Lake City, Utah based medical device company has entered into an agreement with a prominent Japanese partnership to co-develop, market, distribute and sell its proprietary Computerized Bioconductance Test (CB Test) in Japan. In the clinic, the CB Test has demonstrated the ability to provide information that helps physicians accelerate life saving diagnosis and therapy or downgrade risk eliminating anxiety and uncertainty. Despite the recent tsunami tragedy, the Company’s Japanese partners are anxious to move forward bringing the life saving technology to the resilient Japanese market. <<To read a PDF of the full press release, click here. >>

 

Freshmedx Lung Cancer Diagnostic Successfully Evaluates Indeterminate Lung Masses

March 22, 2011 - Freshmedx today announced the completion of a clinical trial at a major medical center in Baltimore. Freshmedx's proprietary Computerized Bioconductance Test (CB Test) showed favorable results in distinguishing between benign and malignant indeterminate masses by chest CT in undiagnosed individuals with lung cancer symptoms. In this trial, the CB Test demonstrated 90% sensitivity and 92% specificity in distinguishing between benign and malignant masses confirmed by biopsy or stable disease.<<To read a PDF of the full press release, click here. >>

 

Joint Venture to Bring Life Saving Technology to Millions in Latin America

July 12, 2010 —Freshmedx today announced the agreement to form a joint venture which will bring life saving technology to over 19 million people in Mexico who are at high risk of developing lung cancer. The Salt Lake City based medical device company, Freshmedx, has entered into an agreement with prominent Mexican partnership to co-develop, market, sell and distribute its Bioconductance Scan Platform (BSP) system in Mexico. <<To read a PDF of the full press release, click here. >>

 

In the "Year of the Lung," Utah Company Freshmedx Announces Breakthrough Lung Cancer Diagnostic

February 18, 2010 - In celebration of World Cancer Day and the Year of the Lung, Freshmedx today announced that it has entered into multiple discussions for the international license of its Bioconductance Scanning Platform (BSP). The BSP is a medical device that can dramatically improve the accuracy of pre-surgical lung cancer diagnosis in a simple and painless 12-minute scan. Freshmedx is pursuing regulatory approvals in the US and has completed CE mark testing for European distribution. <<To read a PDF of the full press release, click here. >> For more information on the Year of the Lung, visit http://www.2010yearofthelung.org/

 

Freshmedx Second Place in the Utah Innovation Awards

April 1, 2009 - The 9th Annual Utah Innovation Awards recognized Freshmedx's CB Scan as the 2nd place medical device in the Utah. This statewide program, the first of its kind, is designed to recognize innovations and the Utah companies that created them. A committee of more than 70 experts from private industry, government and higher education selected the award winners. To read the press release, click here.

 

Freshmedx places at Concept to Company competition

May 20, 2009 - Freshmedx won second place at the 2009 Concept to Company medical device and technology competition. The contest was open to top life science technologies across the state. Freshmedx's technology took 2nd place out of 55 competition applicants. To read about the competition results, click here.

 

Freshmedx presents at the conference for the American Thoracic Society in San Diego, California

May 16, 2009 - Freshmedx, in conjunction with DOCTORS, presented two theses at the American Thoracic Society poster sessions. The theses presented included, "Clinical Evaluation of Transthoracic Bioconductance Scan (TBS) as a Non-invasive Adjunct to CT Scan Diagnosis of Lung Cancer," and, "Technique of Transthoracic Bioconductance Scan (TBS) Technology in the Non-invasive Characterization of Thoracic Malignancies." The American Thoracic Society is a non-profit, international, professional and scientific society for respiratory, critical care and sleep medicine. The ATS is committed to the prevention and treatment of respiratory disease through research, education, patient care and advocacy. For more information about ATS, click here.